Abstract

BackgroundCost-of-illness (COI) studies help identify the economic consequences of a disease like Rheumatoid Arthritis (RA) and are directly relevant to health service decisions and policy- planning. Most COI studies are...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
OP0048 Orthopaedic interventions for RA have changed over the period 1986-2011. An evaluation of joint surgery rates and DMARD/anti-TNF treatment patterns in two UK inception cohorts
...
Annals of the Rheumatic Diseases | VOL. 71
, et. al. ...
01 Jun 2013
Investigation of Rheumatoid Arthritis Genetic Susceptibility Markers in the Early Rheumatoid Arthritis Study Further Replicates the TRAF1 Association with Radiological Damage
Darren Plant ... Anne Barton
The Journal of Rheumatology | VOL. 40
Darren Plant, et. al.Darren Plant ... Anne Barton
15 Dec 2012
THU0248 Three-Year Sustained Remission in Early RA: Predictors and Structural Outcomes. Analysis of Longitudinal Observational Data in Two Multicentre UK Inception Cohorts over 25 Years
S Norton ... A Young
Annals of the Rheumatic Diseases | VOL. 73
S Norton, et. al.S Norton ... A Young
01 Jun 2014
OP0214 Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study (ERAS) provides further replication of the TRAF1/C5 association with radiological damage
J Worthington ... D Symmons
Annals of the Rheumatic Diseases | VOL. 71
J Worthington, et. al.J Worthington ... D Symmons
01 Jun 2013
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers